Skip to main content

Advertisement

Table 1 Baseline characteristics

From: Short term efficacy of nebulized beclomethasone in mild-to-moderate wheezing episodes in pre-school children

  Beclomethasone (BDP group) (N = 110) Salbutamol (Placebo group) (N = 56)
Male, n (%) 64 (58.2) 34 (60.7)
Risk factors for asthma, n (%) 57 (51.8) 30 (53.6)
Age, yr 2.35 ± 0.81 2.29 ± 0.78
Weight, kg 15.4 ± 2.82 14.9 ± 2.74
Height, cm 97.5 ± 9.19 96.0 ± 9.61
Duration of wheezing, yr 1.59 ± 0.87 1.43 ± 0.82
Symptom-free days, % 21.4 ± 18.3 25.9 ± 21.0
Daily coughing score 1.43 ± 0.71 1.35 ± 0.80
Daily Salbutamol use, na 0.49 ± 0.48 0.42 ± 0.35
  1. Values of symptom-free days, daily coughing score and daily salbutamol use are mean of the 2-week run-in period ± SD. Beclomethasone = beclomethasone dipropionate; a number of nebulizations per day.